Liposomal micronutrient intake

  • 2026 October 16.
  • 1319 megtekintés

Summary for doctors

Based on four decades of experience, the doctors at the Lyme Borreliosis Foundation can state that adequate vitamin supplementation is a fundamental requirement in the treatment of Lyme disease and chronic infections. The preparatory and supplementary protocol compiled by our team of doctors to support treatment also recommends the supplementation of vitamins and trace elements to support the immune system.

New technologies can help improve the absorption and utilisation of vitamins. We believe it is important that healthcare professionals treating patients with Lyme disease are also made aware of these new solutions.

What is the question about?

The absorption of micronutrients taken orally is not proportional to the number of milligrams ingested. The best-documented example is vitamin C: a single dose of 200 mg is absorbed in its entirety, but above 500 mg the proportion absorbed decreases and the excess is excreted. Absorption gradually deteriorates as the dose is increased. [1]

Liposomal technology attempts to address this limitation through formulation. A liposome is a vesicle bounded by a phospholipid bilayer, containing an aqueous interior with two loading compartments. The aqueous core accommodates water-soluble substances (vitamin C, B vitamins), whilst the lipid bilayer accommodates fat-soluble substances (CoQ10, vitamins A, D, E and K). [2] The performance of the technology therefore varies depending on the nutrient.

What do human studies show

Vitamin C. Carr’s 2025 exploratory review identified ten comparative human trials. In nine of these, the liposomal form resulted in higher plasma bioavailability. The results varied considerably: Cmax ranged from 1.2 to 5.4 times, whilst AUC ranged from 1.3 to 7.2 times (maximum plasma concentration = Cmax; area under the curve, i.e. the total amount absorbed = AUC). The studies used different products and sampling schedules, and doses ranged from 0.15 to 10 g. [3]

In the best-designed study, Purpura and colleagues compared the two formulations at an identical dose of 500 mg in 27 healthy adults. The study was randomised, double-blind, placebo-controlled and cross-over. The liposomal formulation achieved a 27 per cent higher Cmax and a 21 per cent higher AUC in plasma. In leukocytes, Cmax was 20 per cent higher and AUC was 8 per cent higher. All these differences were statistically significant. [4]

The leukocyte data are significant because the antimicrobial action of vitamin C takes place largely within the cell. This is the only compartment in which a liposomal advantage has been demonstrated under double-blind, dose-matched conditions.

Coenzyme Q10. In a randomised, double-blind, placebo-controlled, crossover trial by Jäger and colleagues, 18 adults received an identical dose of 100 mg. The liposomal formulation resulted in a 31.3 per cent higher Cmax and a 22.6 per cent higher AUC. [5]

Fat-soluble vitamins. Liposomal vitamin D3 raised 25(OH)D3 levels more rapidly than the oil-based form. The difference was greatest in those with severe deficiency. [6] In a multicentre, randomised trial involving 100 participants, the liposomal formulation resulted in higher levels of vitamins D3 and E over a three-month period in patients with cystic fibrosis and pancreatic insufficiency. [7] The participants suffered from fat malabsorption.

Iron and multivitamins. In a randomised, crossover trial by Tinsley et al. involving twenty-five participants, the incremental AUC of iron from the liposomal formulation was 50 per cent higher than that of a conventional formulation with matched nutrient content. [8]

Further findings

  • The benefit is product-dependent. The studies relate to specific, analytically characterised formulations. The ‘liposomal’ label alone does not prove the benefit, and there is no pharmacopoeial standard for it in dietary supplements.
  • Liposomal administration is not faster. In the two best studies, the time taken to reach maximum concentration was the same. The measurable difference was a longer duration of action.

Lyme borreliosis and inflammatory conditions

According to a review by McMillan and colleagues, certain circulating micronutrient levels may be lower in the presence of infection and chronic inflammation. This is partly explained by transient changes in distribution caused by systemic inflammation. A low laboratory value does not in itself prove a deficiency: it must be assessed in conjunction with the clinical picture and inflammatory markers. [9]

In Lyme borreliosis, micronutrient supplementation is not an anti-infective treatment and does not replace guideline-based therapy. Research to date has described metabolic abnormalities in certain patient groups, but has not confirmed any Lyme-related malabsorption. [10]

A practical consideration: Doxycycline is a tetracycline and forms chelates with divalent metal cations (iron, magnesium, calcium, aluminium). Concomitant intake of preparations containing minerals can significantly reduce the absorption of the antibiotic. A three-hour interval between doses resolves this issue. This does not affect vitamin C.

What to ask about a preparation

Liposomal technology is a genuine formulation tool. However, the benefits are specific to the particular preparation, so the only reliable basis for distinguishing between products is the documentation:

  1. Particle size and size distribution (polydispersity index), specifying the measurement method.
  2. Encapsulation efficiency, i.e. the proportion of the active ingredient actually present in the carrier.
  3. Phospholipid composition and source.
  4. Stability data covering the entire shelf life.
  5. A dose-adjusted human pharmacokinetic study for the product in question.

Summary

Where targeted oral replacement is indicated and the formulation has been analytically characterised, the liposomal form may be a modern choice.

References

  1. Levine M, et al. Proc Natl Acad Sci U S A. 1996;93(8):3704–3709. PMID 8623000.
  2. He H, et al. Acta Pharm Sin B. 2019;9(1):36–48. PMID 30766776.
  3. Carr AC. Basic Clin Pharmacol Toxicol. 2025;137(1):e70067. PMID 40506693.
  4. Purpura M, et al. Eur J Nutr. 2024;63(8):3037–3046. PMID 39237620.
  5. Jäger R, et al. Front Nutr. 2025;12:1605033. PMID 41041129.
  6. Dałek P, et al. Nanomedicine. 2022;43:102552. PMID 35346834.
  7. Nowak JK, et al. J Clin Med. 2022;11(2):462. PMID 35054157.
  8. Tinsley GM, et al. Nutrients. 2022;14(16):3321. PMID 36014827.
  9. McMillan DC, et al. Proc Nutr Soc. 2019;78(1):56–67. PMID 30220267.
  10. Fitzgerald BL, et al. Clin Infect Dis. 2021;73(7):e2342–e2349. PMID 32975577.

This article is intended as scientific background material and does not constitute individual medical advice. Dietary supplements do not treat or cure diseases, nor do they replace medical care. The Lyme Borreliosis Foundation does not receive funding from the distributor of liposomal products.

(C) Lyme Borreliosis Foundation